0001213900-24-003538.txt : 20240116 0001213900-24-003538.hdr.sgml : 20240116 20240116083022 ACCESSION NUMBER: 0001213900-24-003538 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240111 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240116 DATE AS OF CHANGE: 20240116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 24533756 BUSINESS ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 8-K 1 ea191607-8k_180life.htm CURRENT REPORT
false 0001690080 0001690080 2024-01-11 2024-01-11 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-01-11 2024-01-11 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-01-11 2024-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): January 11, 2024

 

180 LIFE SCIENCES CORP.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38105   90-1890354
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

   94306
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 507-0669

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ATNF   The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock   ATNFW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. (the “Company”) with the Securities and Exchange Commission (the “Commission” or the “SEC”) on November 16, 2023, on November 15, 2023, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Rule”) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported a stockholders’ deficit of ($149,327), which is below the minimum stockholders’ equity required for continued listing pursuant to the Rule. Additionally, the Company does not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.

 

Nasdaq provided the Company until January 2, 2024 to submit to Nasdaq a plan to regain compliance. We submitted the plan to regain compliance in a timely manner, and on January 11, 2023, Nasdaq advised the Company that it has determined to grant the Company an extension to regain compliance with the Rule.

 

The terms of the extension are as follows: on or before May 13, 2024, the Company must complete certain transactions described in greater detail in the compliance plan, contemplated to result in the Company increasing its stockholders’ equity to more than $2.5 million, and opt for one of the two following alternatives to evidence compliance with the Rule: Alternative 1: The Company must furnish to the SEC and Nasdaq a publicly available report (e.g., a Form 8-K) including: 1. A disclosure of Staff’s deficiency letter and the specific deficiency(ies) cited; 2. A description of the completed transaction or event that enabled the Company to satisfy the stockholders’ equity requirement for continued listing; and 3. An affirmative statement that, as of the date of the report, the Company believes it has regained compliance with the stockholders’ equity requirement based upon the specific transaction or event referenced in Step 2; or Alternative 2: The Company must furnish to the SEC and Nasdaq a publicly available report including: 1. Steps 1 & 2 set forth above; 2. A balance sheet no older than 60 days with pro forma adjustments for any significant transactions or event occurring on or before the report date; and 3. that the Company believes it satisfies the stockholders’ equity requirement as of the report date. The pro forma balance sheet must evidence compliance with the stockholders’ equity requirement.

 

Additionally, in either case the Company is required to disclose that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, that it may be subject to delisting.

 

Regardless of which alternative the Company chooses, if the Company fails to evidence compliance upon filing its next periodic report with the SEC following the end of such compliance period (i.e., its Quarterly Report for the Quarter ended June 30, 2024), the Company may be subject to delisting. In the event the Company does not satisfy these terms, Nasdaq will provide written notification that its securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel.

 

The Company is currently evaluating various courses of action to regain compliance and is hopeful that it can regain compliance with Nasdaq’s minimum stockholders’ equity standard within the compliance period. However, there can be no assurance that the Company will be able to complete the transactions contemplated in the compliance plan, which the Company expects will allow it to regain compliance with the Rule, or that such transactions will result in the Company regaining compliance with the Rule, within the compliance period granted by Nasdaq, if at all.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 16, 2024

 

  180 LIFE SCIENCES CORP.
   
  By:  /s/ James N. Woody, M.D., Ph.D.
    Name:  James N. Woody, M.D., Ph.D.
    Title: Chief Executive Officer

 

 

2

 

 EX-101.SCH 2 atnf-20240111.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 atnf-20240111_def.xml XBRL DEFINITION FILE EX-101.LAB 4 atnf-20240111_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants to purchase shares of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 atnf-20240111_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 11, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 11, 2024
Entity File Number 001-38105
Entity Registrant Name 180 LIFE SCIENCES CORP.
Entity Central Index Key 0001690080
Entity Tax Identification Number 90-1890354
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3000 El Camino Real
Entity Address, Address Line Two Bldg. 4
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94306
City Area Code 650
Local Phone Number 507-0669
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ATNF
Security Exchange Name NASDAQ
Warrants to purchase shares of Common Stock  
Title of 12(b) Security Warrants to purchase shares of Common Stock
Trading Symbol ATNFW
Security Exchange Name NASDAQ
XML 7 ea191607-8k_180life_htm.xml IDEA: XBRL DOCUMENT 0001690080 2024-01-11 2024-01-11 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-01-11 2024-01-11 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-01-11 2024-01-11 iso4217:USD shares iso4217:USD shares false 0001690080 8-K 2024-01-11 180 LIFE SCIENCES CORP. DE 001-38105 90-1890354 3000 El Camino Real Bldg. 4 Suite 200 Palo Alto CA 94306 650 507-0669 false false false false Common Stock, par value $0.0001 per share ATNF NASDAQ Warrants to purchase shares of Common Stock ATNFW NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://180lifesciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports atnf-20240111.xsd atnf-20240111_def.xml atnf-20240111_lab.xml atnf-20240111_pre.xml ea191607-8k_180life.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea191607-8k_180life.htm": { "nsprefix": "ATNF", "nsuri": "http://180lifesciences.com/20240111", "dts": { "schema": { "local": [ "atnf-20240111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "atnf-20240111_def.xml" ] }, "labelLink": { "local": [ "atnf-20240111_lab.xml" ] }, "presentationLink": { "local": [ "atnf-20240111_pre.xml" ] }, "inline": { "local": [ "ea191607-8k_180life.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://180lifesciences.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191607-8k_180life.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191607-8k_180life.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "ATNF_CommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciences.com/20240111", "localname": "CommonStockParValue0.0001PerShareMember", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciences.com/20240111", "localname": "WarrantsToPurchaseSharesOfCommonStockMember", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of Common Stock" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://180lifesciences.com/role/Cover" ], "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-24-003538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-003538-xbrl.zip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end